A curative combination cancer therapy achieves high fractional cell killing through low cross-resistance and drug additivity.
Saved in:
| Title: | A curative combination cancer therapy achieves high fractional cell killing through low cross-resistance and drug additivity. |
|---|---|
| Authors: | Palmer AC; Laboratory of Systems Pharmacology, Harvard Medical School, Boston, United States., Chidley C; Laboratory of Systems Pharmacology, Harvard Medical School, Boston, United States., Sorger PK; Laboratory of Systems Pharmacology, Harvard Medical School, Boston, United States.; Department of Systems Biology, Harvard Medical School, Boston, United States. |
| Source: | ELife [Elife] 2019 Nov 19; Vol. 8. Date of Electronic Publication: 2019 Nov 19. |
| Publication Type: | Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: eLife Sciences Publications, Ltd Country of Publication: England NLM ID: 101579614 Publication Model: Electronic Cited Medium: Internet ISSN: 2050-084X (Electronic) Linking ISSN: 2050084X NLM ISO Abbreviation: Elife Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
